☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - August 2018

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2018 (PDF).

This issue advises of the risk of serious liver injury and new restrictions introduced for ulipristal acetate (Esmya®). It is now recommended that treatment is initiated and supervised by physicians experienced in the diagnosis and treatment of uterine fibroid for:

  • the intermittent treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age who are not eligible for surgery
  • one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age

It is also contraindicated in women with underlying liver disorders and regular liver function monitoring during and immediately after treatment is recommended.

Finally this month, the summary of letters to healthcare professionals includes further information about pregnancy prevention programme materials to support safe use of valproate containing medicines in girls and women of child bearing potential.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - August 2018' by emailShare 'Drug Safety Update - August 2018' on FacebookShare 'Drug Safety Update - August 2018' on TwitterShare 'Drug Safety Update - August 2018' on LinkedInShare 'Drug Safety Update - August 2018' on reddit


No Comments to “Drug Safety Update - August 2018”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.